Skip to main content
Erschienen in: Tumor Biology 4/2014

01.04.2014 | Research Article

Lack of association between MTHFD1 G401A polymorphism and ovarian cancer susceptibility

verfasst von: Yuling Cui, Yanhua Jing, Zihan Sun

Erschienen in: Tumor Biology | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

Published studies on the association between methylenetetrahydrofolate dehydrogenase 1 (MTHFD1) G401A polymorphism and ovarian cancer risk have yielded conflicting results. In order to derive a more precise estimation of the relationship between G401A polymorphism and ovarian cancer risk, the present meta-analysis was performed. All eligible studies on G401A polymorphism and ovarian cancer risk were collected from the PubMed and the Cochrane Library. Statistical analyses were performed by Review Manage 5.0 and Stata 11.0. Our analysis suggested that G401A polymorphism was not associated with ovarian cancer risk when using additive (odds ratio (OR) = 1.72, 95 % confidence interval (CI) = 1.34–2.20, P < 0.0001), recessive (OR = 1.46, 95 % CI = 1.21–1.77, P < 0.0001), dominant (OR = 1.36, 95 % CI = 1.10–1.69, P = 0.004), and allelic models (OR = 1.30, 95 % CI = 1.15–1.47, P < 0.0001) to analyze the data. This meta-analysis suggests that G401A polymorphism might not be a risk factor for ovarian cancer risk. However, further well-designed studies are required to confirm our findings.
Literatur
1.
Zurück zum Zitat Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96.PubMedCrossRef Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96.PubMedCrossRef
2.
Zurück zum Zitat Sabatier R, Gonçalves A, Bertucci F, Capiello MA, Rousseau F, Lambaudie E, et al. Are there candidates for high-dose chemotherapy in ovarian carcinoma? J Exp Clin Cancer Res. 2012;31:87.PubMedCentralPubMedCrossRef Sabatier R, Gonçalves A, Bertucci F, Capiello MA, Rousseau F, Lambaudie E, et al. Are there candidates for high-dose chemotherapy in ovarian carcinoma? J Exp Clin Cancer Res. 2012;31:87.PubMedCentralPubMedCrossRef
3.
Zurück zum Zitat Takano M, Tsuda H, Sugiyama T. Clear cell carcinoma of the ovary: is there a role of histology-specific treatment? J Exp Clin Cancer Res. 2012;31:53.PubMedCentralPubMedCrossRef Takano M, Tsuda H, Sugiyama T. Clear cell carcinoma of the ovary: is there a role of histology-specific treatment? J Exp Clin Cancer Res. 2012;31:53.PubMedCentralPubMedCrossRef
4.
Zurück zum Zitat Hassan MK, Watari H, Han Y, Mitamura T, Hosaka M, Wang L, et al. Clusterin is a potential molecular predictor for ovarian cancer patient’s survival: targeting clusterin improves response to paclitaxel. J Exp Clin Cancer Res. 2011;30:113.PubMedCentralPubMedCrossRef Hassan MK, Watari H, Han Y, Mitamura T, Hosaka M, Wang L, et al. Clusterin is a potential molecular predictor for ovarian cancer patient’s survival: targeting clusterin improves response to paclitaxel. J Exp Clin Cancer Res. 2011;30:113.PubMedCentralPubMedCrossRef
5.
Zurück zum Zitat Plotti F, Capriglione S, Terranova C, Montera R, Aloisi A, Damiani P, et al. Does HE4 have a role as biomarker in the recurrence of ovarian cancer? Tumor Biol. 2012;33:2117–23.CrossRef Plotti F, Capriglione S, Terranova C, Montera R, Aloisi A, Damiani P, et al. Does HE4 have a role as biomarker in the recurrence of ovarian cancer? Tumor Biol. 2012;33:2117–23.CrossRef
6.
Zurück zum Zitat Deng B, Zhang S, Miao Y, Han Z, Zhang X, Wen F, et al. Adrenomedullin expression in epithelial ovarian cancers and promotes HO8910 cell migration associated with upregulating integrin α5β1 and phosphorylating FAK and paxillin. J Exp Clin Cancer Res. 2012;31:19.PubMedCentralPubMedCrossRef Deng B, Zhang S, Miao Y, Han Z, Zhang X, Wen F, et al. Adrenomedullin expression in epithelial ovarian cancers and promotes HO8910 cell migration associated with upregulating integrin α5β1 and phosphorylating FAK and paxillin. J Exp Clin Cancer Res. 2012;31:19.PubMedCentralPubMedCrossRef
7.
Zurück zum Zitat Raji R, Guzzo F, Carrara L, Varughese J, Cocco E, Bellone S, et al. Uterine and ovarian carcinosarcomas overexpressing Trop-2 are sensitive to hRS7, a humanized anti-Trop-2 antibody. J Exp Clin Cancer Res. 2011;30:106.PubMedCentralPubMedCrossRef Raji R, Guzzo F, Carrara L, Varughese J, Cocco E, Bellone S, et al. Uterine and ovarian carcinosarcomas overexpressing Trop-2 are sensitive to hRS7, a humanized anti-Trop-2 antibody. J Exp Clin Cancer Res. 2011;30:106.PubMedCentralPubMedCrossRef
8.
Zurück zum Zitat Zhang H, Ma H, Li L, Zhang Z, Xu Y. Association of methylenetetrahydrofolate dehydrogenase 1 polymorphisms with cancer: a meta-analysis. PLoS One. 2013;8:e69366.PubMedCentralPubMedCrossRef Zhang H, Ma H, Li L, Zhang Z, Xu Y. Association of methylenetetrahydrofolate dehydrogenase 1 polymorphisms with cancer: a meta-analysis. PLoS One. 2013;8:e69366.PubMedCentralPubMedCrossRef
10.
Zurück zum Zitat Zhang H, Xu Y, Zhang Z, Liu R, Ma B. Association between COX-2 rs2745557 polymorphism and prostate cancer risk: a systematic review and meta-analysis. BMC Immunol. 2012;13:14.PubMedCentralPubMedCrossRef Zhang H, Xu Y, Zhang Z, Liu R, Ma B. Association between COX-2 rs2745557 polymorphism and prostate cancer risk: a systematic review and meta-analysis. BMC Immunol. 2012;13:14.PubMedCentralPubMedCrossRef
12.
Zurück zum Zitat Ma E, Iwasaki M, Junko I, Hamada GS, Nishimoto IN, Carvalho SM, et al. Dietary intake of folate, vitamin B6, and vitamin B12, genetic polymorphism of related enzymes, and risk of breast cancer: a case–control study in Brazilian women. BMC Cancer. 2009;9:122.PubMedCentralPubMedCrossRef Ma E, Iwasaki M, Junko I, Hamada GS, Nishimoto IN, Carvalho SM, et al. Dietary intake of folate, vitamin B6, and vitamin B12, genetic polymorphism of related enzymes, and risk of breast cancer: a case–control study in Brazilian women. BMC Cancer. 2009;9:122.PubMedCentralPubMedCrossRef
13.
Zurück zum Zitat Friso S, Choi SW. Gene-nutrient interactions in one-carbon metabolism. Curr Drug Metab. 2005;6:37–46.PubMedCrossRef Friso S, Choi SW. Gene-nutrient interactions in one-carbon metabolism. Curr Drug Metab. 2005;6:37–46.PubMedCrossRef
14.
Zurück zum Zitat Linhart HG, Troen A, Bell GW, Cantu E, Chao WH, Moran E, et al. Folate deficiency induces genomic uracil misincorporation and hypomethylation but does not increase DNA point mutations. Gastroenterology. 2009;136:227–35.PubMedCentralPubMedCrossRef Linhart HG, Troen A, Bell GW, Cantu E, Chao WH, Moran E, et al. Folate deficiency induces genomic uracil misincorporation and hypomethylation but does not increase DNA point mutations. Gastroenterology. 2009;136:227–35.PubMedCentralPubMedCrossRef
15.
Zurück zum Zitat Hum DW, Bell AW, Rozen R, MacKenzie RE. Primary structure of a human trifunctional enzyme: isolation of a cDNA encoding methylenetetrahydrofolate-dehydrogenase, methenyltetrahydrofolate-cyclohydrolase, formyltetrahydrofolate synthetase. J Biol Chem. 1998;263:15946–50. Hum DW, Bell AW, Rozen R, MacKenzie RE. Primary structure of a human trifunctional enzyme: isolation of a cDNA encoding methylenetetrahydrofolate-dehydrogenase, methenyltetrahydrofolate-cyclohydrolase, formyltetrahydrofolate synthetase. J Biol Chem. 1998;263:15946–50.
16.
Zurück zum Zitat Wang N, Zhang H, Yao Q, Wang Y, Dai S, Yang X. TGFBI promoter hypermethylation correlating with paclitaxel chemoresistance in ovarian cancer. J Exp Clin Cancer Res. 2012;31:6.PubMedCentralPubMedCrossRef Wang N, Zhang H, Yao Q, Wang Y, Dai S, Yang X. TGFBI promoter hypermethylation correlating with paclitaxel chemoresistance in ovarian cancer. J Exp Clin Cancer Res. 2012;31:6.PubMedCentralPubMedCrossRef
17.
Zurück zum Zitat Duthie SJ. Folic acid deficiency and cancer: mechanisms of DNA instability. Br Med Bull. 1999;55:578–92.PubMedCrossRef Duthie SJ. Folic acid deficiency and cancer: mechanisms of DNA instability. Br Med Bull. 1999;55:578–92.PubMedCrossRef
19.
Zurück zum Zitat Laatio L, Myllynen P, Serpi R, Rysä J, Ilves M, Lappi-Blanco E, et al. BMP-4 expression has prognostic significance in advanced serous ovarian carcinoma and is affected by cisplatin in OVCAR-3 cell s. Tumor Biol. 2011;32:985–95.CrossRef Laatio L, Myllynen P, Serpi R, Rysä J, Ilves M, Lappi-Blanco E, et al. BMP-4 expression has prognostic significance in advanced serous ovarian carcinoma and is affected by cisplatin in OVCAR-3 cell s. Tumor Biol. 2011;32:985–95.CrossRef
20.
Zurück zum Zitat Guan X, Zhang N, Yin Y, Kong B, Yang Q, Han Z, et al. Polymorphisms in the p63 and p73 genes are associated with ovarian cancer risk and clinicopathological variables. J Exp Clin Cancer Res. 2012;31:89.PubMedCentralPubMedCrossRef Guan X, Zhang N, Yin Y, Kong B, Yang Q, Han Z, et al. Polymorphisms in the p63 and p73 genes are associated with ovarian cancer risk and clinicopathological variables. J Exp Clin Cancer Res. 2012;31:89.PubMedCentralPubMedCrossRef
21.
Zurück zum Zitat Brody LC, Conley M, Cox C, Kirke PN, McKeever MP, Mills JL. A polymorphism, R653Q, in the trifunctional enzyme methylenetetrahydrofolate dehydrogenase/methenyltetrahydrofolate cyclohydrolase/formyltetrahydrofolate synthetase is a maternal genetic risk factor for neural tube defects: report of the Birth Defects Research Group. Am J Hum Genet. 2002;71:1207–15.PubMedCentralPubMedCrossRef Brody LC, Conley M, Cox C, Kirke PN, McKeever MP, Mills JL. A polymorphism, R653Q, in the trifunctional enzyme methylenetetrahydrofolate dehydrogenase/methenyltetrahydrofolate cyclohydrolase/formyltetrahydrofolate synthetase is a maternal genetic risk factor for neural tube defects: report of the Birth Defects Research Group. Am J Hum Genet. 2002;71:1207–15.PubMedCentralPubMedCrossRef
22.
Zurück zum Zitat Chen LH, Liu ML, Hwang HY, Chen LS, Shane B. Human methionine synthase: cDNA cloning, gene localization, and expression. J Biol Chem. 1997;272:3628–34.PubMedCrossRef Chen LH, Liu ML, Hwang HY, Chen LS, Shane B. Human methionine synthase: cDNA cloning, gene localization, and expression. J Biol Chem. 1997;272:3628–34.PubMedCrossRef
23.
Zurück zum Zitat Kelemen LE, Goodman MT, McGuire V, Rossing MA, Webb PM, Köbel M, et al. Genetic variation in TYMS in the one-carbon transfer pathway is associated with ovarian carcinoma types in the Ovarian Cancer Association Consortium. Cancer Epidemiol Biomarkers Prev. 2010;19:1822–30.PubMedCentralPubMedCrossRef Kelemen LE, Goodman MT, McGuire V, Rossing MA, Webb PM, Köbel M, et al. Genetic variation in TYMS in the one-carbon transfer pathway is associated with ovarian carcinoma types in the Ovarian Cancer Association Consortium. Cancer Epidemiol Biomarkers Prev. 2010;19:1822–30.PubMedCentralPubMedCrossRef
24.
Zurück zum Zitat Granato T, Midulla C, Longo F, Colaprisca B, Frati L, Anastasi E. Role of HE4, CA72.4, and CA125 in monitoring ovarian cancer. Tumor Biol. 2012;33:1335–9.CrossRef Granato T, Midulla C, Longo F, Colaprisca B, Frati L, Anastasi E. Role of HE4, CA72.4, and CA125 in monitoring ovarian cancer. Tumor Biol. 2012;33:1335–9.CrossRef
25.
Zurück zum Zitat Midulla C, Manganaro L, Longo F, Viggiani V, Frati L, Granato T, et al. HE4 combined with MDCT imaging is a good marker in the evaluation of disease extension in advanced epithelial ovarian carcinoma. Tumor Biol. 2012;33:1291–8.CrossRef Midulla C, Manganaro L, Longo F, Viggiani V, Frati L, Granato T, et al. HE4 combined with MDCT imaging is a good marker in the evaluation of disease extension in advanced epithelial ovarian carcinoma. Tumor Biol. 2012;33:1291–8.CrossRef
26.
Zurück zum Zitat Xu Y, Li Q, Li XY, Yang QY, Xu WW, Liu GL. Short-term anti-vascular endothelial growth factor treatment elicits vasculogenic mimicry formation of tumors to accelerate metastasis. J Exp Clin Cancer Res. 2012;31:16.PubMedCentralPubMedCrossRef Xu Y, Li Q, Li XY, Yang QY, Xu WW, Liu GL. Short-term anti-vascular endothelial growth factor treatment elicits vasculogenic mimicry formation of tumors to accelerate metastasis. J Exp Clin Cancer Res. 2012;31:16.PubMedCentralPubMedCrossRef
27.
Zurück zum Zitat Smoter M, Bodnar L, Grala B, Stec R, Zieniuk K, Kozlowski W, et al. Tau protein as a potential predictive marker in epithelial ovarian cancer patients treated with paclitaxel/platinum first-line chemotherapy. J Exp Clin Cancer Res. 2013;32:25.PubMedCentralPubMedCrossRef Smoter M, Bodnar L, Grala B, Stec R, Zieniuk K, Kozlowski W, et al. Tau protein as a potential predictive marker in epithelial ovarian cancer patients treated with paclitaxel/platinum first-line chemotherapy. J Exp Clin Cancer Res. 2013;32:25.PubMedCentralPubMedCrossRef
28.
Zurück zum Zitat Macuks R, Baidekalna I, Donina S. An ovarian cancer malignancy risk index composed of HE4, CA125, ultrasonographic score, and menopausal status: use in differentiation of ovarian cancers and benign lesions. Tumor Biol. 2012;33(5):1811–7.CrossRef Macuks R, Baidekalna I, Donina S. An ovarian cancer malignancy risk index composed of HE4, CA125, ultrasonographic score, and menopausal status: use in differentiation of ovarian cancers and benign lesions. Tumor Biol. 2012;33(5):1811–7.CrossRef
29.
30.
Zurück zum Zitat Zhang H, Qi C, Wang A, Yao B, Li L, Wang Y, et al. Prognostication of prostate cancer based on NUCB2 protein assessment: NUCB2 in prostate cancer. J Exp Clin Cancer Res. 2013;32:77.PubMedCentralPubMedCrossRef Zhang H, Qi C, Wang A, Yao B, Li L, Wang Y, et al. Prognostication of prostate cancer based on NUCB2 protein assessment: NUCB2 in prostate cancer. J Exp Clin Cancer Res. 2013;32:77.PubMedCentralPubMedCrossRef
Metadaten
Titel
Lack of association between MTHFD1 G401A polymorphism and ovarian cancer susceptibility
verfasst von
Yuling Cui
Yanhua Jing
Zihan Sun
Publikationsdatum
01.04.2014
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 4/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1446-z

Weitere Artikel der Ausgabe 4/2014

Tumor Biology 4/2014 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.